Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Study (n=885) found people with haematological malignancies had lower antibody responses after 2 Pfizer vaccine doses vs healthcare workers. People on bruton tyrosine kinase inhibitors, ruxolitinib, venetoclax, or anti-CD20 antibodies had lower responses than untreated people.

SPS commentary:

The study also reported breakthrough severe SARS-CoV-2 infections in fully vaccinated patients with haematological malignancies. Based on these findings the study researchers emphasise the importance of ongoing strict adherence to non-pharmacological interventions and household vaccination while SARS-CoV-2 is circulating in the community.

The Lancet Haematology